mTOR-dependent signalling in Alzheimer's disease
1Karolinska Institute, Department of Neurobiology, Care Sciences and Society, KI-ADRC, Stockholm, Sweden. Jin-Jing.Pei@ki.se
Journal of Cellular and Molecular Medicine
|February 13, 2009
Summary
The mechanistic target of rapamycin (mTOR) pathway is implicated in Alzheimer's disease (AD) pathogenesis, influencing neurodegeneration and neurofibrillary degeneration. Understanding mTOR's role may reveal new biomarkers for cognitive impairment in AD.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Alzheimer's disease (AD) involves neurodegeneration and neurofibrillary degeneration, leading to cognitive impairments.
- The precise factors governing neuronal fate in AD remain unclear.
- Emerging evidence suggests a role for mechanistic target of rapamycin (mTOR)-dependent signaling in AD neuropathology.
Purpose of the Study:
- To review the involvement of mTOR-dependent signaling in the pathogenesis of Alzheimer's disease.
- To summarize recent advancements in understanding mTOR's role in neurodegeneration and neurofibrillary degeneration.
- To explore the potential of mTOR-related signaling components as biomarkers for cognitive impairment in AD.
Main Methods:
- Literature review of studies investigating mTOR signaling in AD.
- Analysis of research on neurodegeneration and neurofibrillary degeneration in the context of mTOR.
- Examination of clinical studies assessing mTOR-related biomarkers for cognitive function in AD patients.
Main Results:
- mTOR-dependent signaling is implicated in both neurodegeneration and neurofibrillary degeneration in AD brains.
- Dysregulation of mTOR pathways contributes to the progression of AD pathology.
- Certain mTOR-related signaling components show promise as potential biomarkers for cognitive decline in AD.
Conclusions:
- mTOR-dependent signaling is a critical factor in Alzheimer's disease pathogenesis.
- Targeting mTOR pathways may offer therapeutic strategies for AD.
- mTOR-related signaling components warrant further investigation as diagnostic and prognostic biomarkers for AD.
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...